JournalArta
Sunday, November 8, 2026 · JakartaS&P 7,376.86 ▲0.32%USD/IDR 18,004 ▼0.25%Subscribe
JournalArta
Global Edition
beyond headlines
Advertisement
Markets · Stocks

Emerson Electric (EMR) Stock Falls 4.59% on Thursday, Testing Support Level

On November 5, 2026: price 162.61 USD, trend sideways, RSI 49.9, support 160.29, resistance 170.74. technical analysis of emr stock.

By Alistair Sterling
November 6, 20264 min read
Advertisement
Emerson Electric (EMR) Stock Falls 4.59% on Thursday, Testing Support Level
Logo Emerson Electric — JournalArta illustration

Why EMR is in focus today

  • One-day move of -4.59%, about 1.3× its average daily range (ATR)
  • Volume at 1.9× the 20-day average
  • MACD histogram has just turned negative
  • Not covered by JournalArta in the last 14 days

Selected automatically from 80 NYSE (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

Emerson Electric fell 4.59% on Thursday, November 5, to $162.61, with trading volume reaching 1.9 times its 20-day average. The move matters beyond one industrial stock: Emerson supplies automation and technology used across industries, so its share-price swings can reflect changing expectations for industrial demand. The technical picture is mixed, with the sharp decline arriving as momentum weakened but buyers still active.
Advertisement

Trend & Price Action

The latest close was below the 20-day moving average of $163.76 but above the 50-day average of $157.81. That places the shares in a short-term pullback within a broader price structure that has not yet broken below the longer average. The 20-day average itself rose 0.82% over five days, a sign the recent weakness has not erased its mild upward slope. No new moving-average crossover was recorded. The share price sits in the lower portion of its recent range: 22% of the way from the 20-day support at $160.29 to resistance at $170.74. Its 3-month range runs from $144.40 to $172.00. A close below the 20-day average therefore signals pressure, but the nearby support and higher 50-day average are important tests before calling the broader structure broken.
Price action chart of EMR
3-month price action chart of EMR: price, SMA20/50, Bollinger, support & resistance.
The session’s decline was about 1.3 times the average daily range, while volume jumped to 5,876,500 shares from a 20-day average of 3,173,770. That combination means the sell-off attracted more participation than usual; it is a stronger warning than a similar move on thin trading. Yet OBV, a running measure of buying and selling volume, was rising, suggesting that accumulated volume has not confirmed a sustained shift toward distribution.
Advertisement

Oscillators & Momentum

Momentum indicators do not yet show a decisive washout or rebound. RSI was 49.9, a neutral reading around the midpoint of its scale, while Stochastic %K at 46.3 and %D at 69.4 were also classified as neutral. The technical bias flags RSI rolling over from above 65, which points to fading momentum even though its current level is not extreme. MACD was 2.305 against a signal line of 2.349, leaving its histogram at -0.044. The histogram has just turned negative, a bearish shift in momentum rather than proof of a full trend reversal. This is one of the clearest reasons for caution after the high-volume decline. The indicators’ mixed readings fit a neutral bias: the pullback is real, but the price remains above the 50-day average.
Momentum chart of EMR
Momentum chart of EMR: RSI(14), MACD, Stochastic.

Volatility & Key Levels

The Bollinger Bands are narrowing, with a 7.6% band width, while the price sits at 41% of the range between the lower and upper bands. A squeeze means recent price variation has contracted; it can precede a larger move, but does not indicate its direction. The latest decline may be testing the lower part of the structure, though price remains above the lower band at $157.55. ATR was $5.59, or 3.4% of the share price, indicating moderate volatility. Support at $160.29 is the immediate level to watch; a break below it would expose the lower Bollinger Band at $157.55 and the 50-day average at $157.81. On the upside, the 20-day resistance at $170.74 sits just below the 3-month high of $172.00. A move through that area would be needed to show buyers have reclaimed the recent range. The ATR-based reference levels are $154.23 below and $170.99 above, underscoring how far a typical volatility-adjusted move could extend.
Advertisement

Fundamental Context

According to its SEC filing, Emerson reported quarterly revenue of $4.87 billion for the quarter ended June 30, 2026, up 7.0% from $4.55 billion a year earlier. Net income was $718.0 million, compared with $586.0 million, and diluted earnings per share were $1.28. The company filed a Form 8-K on November 4 reporting results of operations and financial condition. These results provide a firmer operating backdrop, but the near-term verdict here remains driven by price and momentum signals.

Technical Verdict: HOLD

The neutral technical bias supports HOLD: price is below the 20-day average, MACD momentum has turned negative, but the shares remain above the 50-day average and OBV is rising. The verdict is invalidated if price falls below the 20-day support at $160.29, which would weaken the current case that the pullback is contained. - Ideal entry range: $157.55–$160.29, the lower Bollinger Band to 20-day support zone. - Exit target: $170.74, the 20-day resistance. - Stop-loss protection: $154.23, the price-minus-1.5-ATR reference level. In plain English, the signals are mixed, so the chart does not yet show a clear direction.
Advertisement

Summary Data EMR

Last price162.61 USD
Change 1 day / 5 days / 1 month-4.59% / -4.76% / 2.23%
Trend / MA-crosssideways / none
SMA20 / SMA50163.76 / 157.81
RSI (14) / Stochastic %K49.9 / 46.3
Bollinger %B / ATR41% / 5.59
Support / Resistance 20 days160.29 / 170.74
Data as of6 November 2026 04:00 WIB

Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

Advertisement
Advertisement

Latest News

All stories →
  1. Sport · BasketballKevin Durant Returns as Rockets Visit Suns in PhoenixNov 8
  2. Lifestyle · Food & HealthAmy Leslie Continues Breast Cancer Charity Founded by Her Mother and GrandmotherNov 8
  3. TechnologyNASA Astronaut Applications Open for Moon and Mars MissionsNov 8
  4. Lifestyle · Food & HealthHumans Still Evolving Right: Genes Reflect Diet and AltitudeNov 8
  5. Advertisement
  6. Lifestyle · Food & HealthBird Flu Detected at Pierce County Poultry Facility in WashingtonNov 8
  7. TechnologyGreat Unconformity: How Earth Lost a Billion YearsNov 8
  8. World · Americas & AfricaSecond Windstorm Threatens B.C. South Coast as 40,000 Remain Without PowerNov 8
  9. SportMatt Payne Takes Sandown 500 Pole in 1:08.110Nov 8